Phase 3, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care (Neurorrhaphy) in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair.
Latest Information Update: 21 Mar 2025
At a glance
- Drugs NTX-001 Neuraptive Therapeutics (Primary)
- Indications Peripheral nerve injuries
- Focus Registrational; Therapeutic Use
- Sponsors Neuraptive Therapeutics
Most Recent Events
- 18 Mar 2025 Planned End Date changed from 1 Mar 2027 to 30 Apr 2027.
- 18 Mar 2025 Planned primary completion date changed from 1 Jan 2027 to 31 Mar 2027.
- 18 Mar 2025 Status changed from not yet recruiting to recruiting.